FR

Francie Reintjes

Board Observer at BIOMILQ

Francie Reintjes is a seasoned professional in the life sciences investment sector, currently serving as Vice President of Growth Investments at Novo Holdings since May 2020, where expertise lies in investing in scalable, high-growth companies. Reintjes holds multiple board observer roles, including positions at Route 92 Medical, Evosep Biosystems, Kate Farms, and Invetx, the latter being a notable acquisition by Dechra for up to $520 million. Previous experience includes a founding team role at Incentrum Group, investment banking analysis at Bank of America Merrill Lynch, and internships at Verger Capital Management and Global Prairie. Francie Reintjes earned a Bachelor of Science in Mathematical Business from Wake Forest University.

Location

San Francisco, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


BIOMILQ

1 followers

BIOMILQ is a women-owned and science-led start-up building a mammary biomanufacturing platform to produce bioauthentic human milk ingredients for better human health. By combining the unique capabilities of human mammary cells with a scalable biomanufacturing process, BIOMILQ aims to demonstrate the power of our platform through impact in early life nutrition with ingredients that promote immune, gut, and neurological development.


Industries

Employees

11-50

Links